Scynexis has reported positive data from the Phase III VANISH-306 clinical trial of its new oral therapy, Brexafemme (Ibrexafungerp) to treat vulvovaginal candidiasis (VVC), a vaginal yeast infection caused due to Candida.

An antifungal licensed to treat VVC, Brexafemme works by hindering glucan synthase. It is fungicidal against Candida species and destroys fungal cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The international, multicentre, double-blind, randomised, placebo-controlled trial analysed the efficacy and safety of ibrexafungerp as against placebo in female subjects aged over 12 years with VVC.

Findings showed that ibrexafungerp demonstrated to be superior to placebo in the primary as well as all crucial secondary goals of the trial.

Nearly 63.3% of the subjects in the ibrexafungerp arm had substantially increased clinical cure rates as against 44% in the placebo arm, at the test-of-cure (TOC) day-ten visit.

Day-ten data also showed that ibrexafungerp outperformed placebo in terms of mycological eradication and clinical improvement.

Ibrexafungerp was found to be safe and well-tolerated in the trial with side effects observed to be gastrointestinal in nature and of mild to moderate severity.

Furthermore, the oral antifungal provided lasting clinical effect at day 25 visit with 73.9% in the ibrexafungerp group attaining a complete sign and symptom resolution.

Scynexis chief medical officer David Angulo said: “Ibrexafungerp is a first-in-class, one-day oral therapy that blocks glucan synthase, an enzyme critical for the maintenance of the fungal cell wall, and has shown in vitro fungicidal activity against multiple different Candida species strains, including those that are echinocandin and azole-resistant.”

The US Food and Drug Administration’s approval for Brexafemme to treat VVC is based on data from two Phase III trials, VANISH-303 and VANISH-306, of the VANISH development programme.

In January this year, Mycovia reported positive topline data from the Phase III ultraVIOLET trial of oteseconazole (VT1161), to treat people with recurrent vulvovaginal candidiasis (RVVC).